Why is "Apatinib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-15 19:21:04
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Apatinib entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-04-15 and was most recently seen on 2026-04-15.
Wikipedia Overview
Rivoceranib, also known as apatinib, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2. It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically, rivoceranib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling - Nature
-
Camrelizumab Plus Apatinib Demonstrates Efficacy in Refractory Chordoma - onclive.com
-
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial - Wiley & Sons
-
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial - The Lancet
-
Camrelizumab Plus Apatinib in Refractory Chordoma: A Phase II Clinical Trial - Oncodaily
-
Case Report: Apatinib combined with IMRT concurrent therapy achieves rapid response and significantly prolongs progression-free survival in elderly patients with inoperable locally advanced esophageal squamous cell carcinoma - Frontiers
-
Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study - Nature
-
Fuzuloparib in HER2-Negative Metastatic Breast Cancer With Germline BRCA1/2 Mutations - The ASCO Post
-
Fuzuloparib Maintenance Therapies Improve PFS in Newly Diagnosed Ovarian Cancer - CancerNetwork
-
Fuzuloparib Extends PFS as Maintenance Therapy for Advanced Ovarian Cancer - Oncology Nurse Advisor
-
FDA Review Restarts for Rivoceranib/Camrelizumab in Advanced HCC - Targeted Oncology
-
FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time - Fierce Pharma
-
Dose-dense paclitaxel and novel combination maintenance therapies offer survival benefits in advanced ovarian cancer - ESMO Daily Reporter
-
Oncology Letters - Spandidos Publications
-
Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma - Nature
-
Efficacy and safety of camrelizumab plus apatinib for solid tumors: a meta-analysis - Frontiers
-
Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma - Nature
-
Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial - Nature
-
Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial - Nature
-
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial - Nature
-
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial - Nature
-
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer - Nature
-
Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial - Nature
-
TACE Plus Camrelizumab and Apatinib Improves PFS in Liver Cancer Trial - Oncology News Central
-
Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study - Nature
-
Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2 - Nature
-
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial - Nature
-
Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial - Nature
-
FDA Grants Orphan Drug Designation to Apatinib in Adenoid Cystic Carcinoma - Targeted Oncology
-
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study - Nature
-
Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study - Nature
-
Phase II study of transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma - Nature
-
Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety - Nature
-
Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma - Nature
-
Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1/myosin heavy chain 9 axis - Nature
-
Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis - Nature
-
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma - Nature
-
A gelable polymer loaded with curcumin and apatinib absorbed in gelatin sponge delays postoperative residual tumor growth - Nature
-
Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging - Nature
-
Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial - Nature
-
Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study - Nature
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study - The Lancet
-
Apatinib-induced protective autophagy and apoptosis through the AKT–mTOR pathway in anaplastic thyroid cancer - Nature
-
Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers - Wiley Online Library
-
Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study - Nature
-
Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies - Frontiers
-
The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus - Nature
-
Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study - Nature
-
Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats - Frontiers
-
Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model - Nature
-
SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report - Frontiers
-
Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study - Nature
-
NDUFA4L2 promotes glioblastoma progression, is associated with poor survival, and can be effectively targeted by apatinib - Nature
-
Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer - Nature
-
Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review - Frontiers
-
Apatinib Plus Chemotherapy in Advanced SCLC: Phase II Study - Physician's Weekly
-
Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report - Frontiers
-
Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer - Frontiers
-
Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis - Nature
-
An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma - Wiley Online Library
-
Apatinib manifests an unexpectedly favorable outcome in the management of axillary lymph node follicular dendritic cell sarcoma: a case report - Frontiers
-
FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway - Nature
-
WZB117 enhanced the anti-tumor effect of apatinib against melanoma via blocking STAT3/PKM2 axis - Frontiers
-
The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer - Wiley Online Library
-
Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study - Wiley Online Library
-
Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis - Nature
-
Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer - ESMO Daily Reporter
-
CAP 03-NEO Trial Updates from ASCO 2025: Promising Neoadjuvant Approach in Resectable Stage II/III Acral Melanoma Using Camrelizumab, Apatinib, and Temozolomide - Oncodaily
-
Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature Review - Frontiers
-
Successful treatment of metastatic colorectal cancer with apatinib: re | OTT - Dove Medical Press
-
Case report: Long-term progression-free survival in advanced ovarian cancer treated with apatinib in first-line maintenance treatment - Frontiers
-
Apatinib - Springer Nature Link
-
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet
-
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy - Wiley Online Library
-
Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report - Oncology Nurse Advisor
-
Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric Cancer - onclive.com
-
bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy - Wiley Online Library
-
TACE Plus Camrelizumab/Rivoceranib Extends PFS in Unresectable Liver Cancer - CancerNetwork
-
FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma - CancerNetwork
-
Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib - Frontiers
-
Targeting the VEGFR2 signaling pathway for angiogenesis and fibrosis regulation in neovascular age-related macular degeneration - Nature
-
A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: 125I Seed Implantation Plus Apatinib After Surgery - Frontiers
-
Rivoceranib-Airuika Combo Improves Survival in Liver Cancer Subset - Cure Today
-
Cisplatin/rivoceranib - Springer Nature Link
-
CrystalGenomics' partner seeks FDA nod for camrelizumab drug combo to treat liver cancer - koreabiomed.com
-
Rivoceranib-Based Therapy Improves Outcomes in Recurrent Ovarian Cancer - Cure Today
-
Jiangsu Hengrui Pharma and Elevar Therapeutics Announce - GlobeNewswire
-
The central role of a two-way positive feedback pathway in molecular targeted therapies-mediated pyroptosis in anaplastic thyroid cancer - Wiley Online Library
-
Massive Hepatocellular Carcinoma With Situs Inversus Totalis | PGPM - Dove Medical Press
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.